Good morning, Marco. The Cyclospora outbreak you've been tracking since early July crossed a line yesterday — Michigan reported the first two deaths in the country, and the state's own case count is now above eleven thousand. Second thing worth your five minutes: ACP dropped a policy paper this morning on adult obesity that has a direct bearing on the elderly patients now arriving on your service already on a GLP-1. Everything else is lighter — the Mets finished dismantling the roster, Cuba's grid went down for the sixth time this year, and Trump says he's negotiating with Iran while Tehran says he isn't.
Section A — Top Stories
Three items, all confirmed within the last 48 hours.
Update
First U.S. deaths in the Cyclospora outbreak — both in Michigan, both in patients with underlying illness
The Michigan Department of Health and Human Services announced Monday that two people have died in connection with the cyclosporiasis outbreak — the first deaths recorded in the United States from this parasite. Both had, in the department's words, "significant underlying health conditions that may have been impacted by cyclosporiasis and dehydration." No further detail is being released. Michigan now reports 11,234 cases and 193 hospitalizations since early May, up from 10,386 two weeks ago. Nationally, cases have been reported in 45 states, and CDC's working estimate for the season is roughly 18,000 illnesses. The nine-state Taylor Farms cluster tied to iceberg lettuce served at Taco Bell still sits at 1,947 confirmed cases; the recall was issued July 17. A second, unrelated outbreak with no identified source continues to grow, and Texas cases keep climbing outside the Midwest core.
Sources: NBC News, Aug 3 · Washington Post · Al Jazeera · CDC investigation update
Why it matters to youThe deaths reframe what you've been treating as a nuisance diarrheal illness. The mechanism named — dehydration in a patient with significant comorbidity — is exactly the presentation that lands on your service at 2 a.m.: an 82-year-old with three weeks of watery stools, 8 pounds down, on a diuretic and an ACE inhibitor, creatinine up 0.6 from baseline. The parasite isn't what kills; the volume depletion layered on top of fixed cardiac and renal reserve is. Florida is not in the nine-state lettuce cluster, but the unexplained second outbreak is spreading well outside it.
Suggested actionTreat prolonged non-bloody diarrhea in an older adult this month as a volume problem first and a microbiology problem second — hold the diuretic and the ACE inhibitor on admission rather than continuing them by inertia, and get the multiplex GI PCR up front instead of stool culture and O&P. Confirm your panel actually includes Cyclospora cayetanensis; not all do. TMP-SMX remains first-line, so have the sulfa-allergy alternative decided before you're paged about it.
New
ACP issues a policy position on adult obesity — and it lands in the middle of Medicare's GLP-1 experiment
The American College of Physicians published Public Policy Approaches to Addressing Adult Obesity in this morning's Annals of Internal Medicine, recommending that policymakers address modifiable contributors to obesity and expand the affordability and accessibility of treatment for adults. ACP has consistently backed coverage of FDA-approved anti-obesity medications under Medicare and Medicaid. The timing is not accidental: CMS's Medicare GLP-1 Bridge went live July 1, giving eligible Part D beneficiaries certain anti-obesity drugs for $50 a month, and runs through December 31, 2027. KFF estimates roughly 3.8 million beneficiaries may qualify. The successor BALANCE model was supposed to start in 2027, but Part D plans covering 80% of enrollment declined to volunteer by the April deadline — which is why the Bridge got stretched from six months to eighteen.
Sources: Annals of Internal Medicine, Aug 4 · KFF on the Bridge and BALANCE · CMS program page · Medical Economics on ACP's position
Why it matters to youPractically, the policy debate is upstream of a bedside problem that is already yours. Since July 1 you have a rapidly growing population of Medicare-age adults newly started on semaglutide or tirzepatide for weight rather than diabetes, and the geriatric literature is increasingly uncomfortable about it — longitudinal data in older adults show reductions in handgrip strength and accelerated sarcopenia with prolonged use, beyond what lean-mass measurements alone capture. The elderly patient who is now 25 pounds lighter than at her last admission may also be measurably weaker, and that changes fall risk, delirium risk, and how she tolerates three days of bed rest on your service.
Suggested actionAdd "started a GLP-1 since July?" to your med-rec habit for Medicare-age admissions — the Bridge is new enough that it often won't be on the outside list. When one turns up, document baseline function and grip, not just weight, and think twice before ordering a clear-liquid-then-NPO sequence in someone already on a drug that slows gastric emptying and blunts appetite.
Update
Iran: Trump says talks are under way and calls it a "last chance"; Tehran's foreign ministry says there are no direct talks
Trump said Monday that negotiations with Iran are ongoing and that this is Tehran's "last chance to sign a good document," describing a deal as imminent and centered on the Strait of Hormuz and denuclearisation. He said he called off a major strike Friday at the request of Qatar, Saudi Arabia and the UAE. Iran's foreign ministry publicly contradicted the characterization, saying it is not in direct negotiations with Washington and is instead working through Oman and other regional and extra-regional intermediaries to reduce tension. Foreign Minister Abbas Araghchi said Tehran–Oman talks on the future management of Hormuz are in their "final stages," while President Pezeshkian urged Washington to honour the June 17 memorandum of understanding. Markets took the optimistic read: U.S. stocks moved near record highs Tuesday and oil fell.
Sources: Al Jazeera, Aug 3 · Aug 4 live thread · Al Jazeera markets
Why it matters to youThis is the fourth "talks are starting" moment in about three weeks, and the previous three were each followed by a resumption of strikes within days. What's different this time is the public gap between the two sides' accounts of whether talks exist at all — Trump describing an active negotiation, Tehran describing indirect messaging through Oman. Hold it loosely. The practical read-through for you remains the crude price, which has swung from above $100 to the low $80s and back over the same period.
Section B — The Debate
One live argument, both sides steelmanned, no verdict.
Should drugmakers be allowed to pay 340B discounts as rebates instead of up-front price cuts?
Why it's live right now: HRSA issued its formal notice on July 31 moving the revised 340B Rebate Model Pilot Program forward after more than 2,400 public comments. Manufacturers must submit rebate plans by August 24, with approved plans effective January 1, 2027. The AHA responded the same day that it is "considering all available options" — the last version of this program was blocked by a Maine federal court days before its January 2026 launch.
The case FOR the rebate model
The core claim is that 340B has grown into a $100 billion program with almost no visibility into whether the discounts are going where Congress intended. Under the current replenishment system, a manufacturer sells at the discounted price and only afterward, if ever, learns which claims it applied to — which makes duplicate discounts, where a provider captures both a 340B price and a Medicaid rebate on the same unit, structurally hard to detect. A rebate flips the sequence: the covered entity documents eligibility, then the manufacturer pays. PhRMA argues in "340B Rebate Model: Accountability Over Alarmism" that this imposes no more burden than the replenishment accounting hospitals already do, and that the verification data is exactly what's needed to police duplicates in a targeted way. CEO Steve Ubl has said the industry is "heartened by the administration's efforts to ensure that the program operates as it's intended."
The case AGAINST
The objection is about cash, not principle. Under a rebate, the hospital pays full list price up front and waits to be repaid — which, on high-cost specialty drugs, means safety-net hospitals financing the manufacturer's compliance review out of their own working capital. Rick Pollack, president and CEO of the American Hospital Association, wrote in the association's July 31 statement that HRSA's analysis "dramatically understates the true costs of this program, ignoring the hundreds of millions of dollars in compliance expenses, cash-flow disruptions, and operational burdens that will inevitably divert scarce resources away from patient care," and that rural and underserved hospitals will "spend more on bureaucracy and less on the services and care that patients depend on." AHA put the annual cost to 340B hospitals above $1 billion in its July 15 comment.
Where it might land: Manufacturer rebate plans are due August 24 and the pilot is scheduled to take effect January 1, 2027 — but a July 21 court ruling already held that companies may not impose a rebate model without HHS approval, and AHA has signalled it may litigate again, so the January date is not settled.